Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer

被引:31
|
作者
Mabuchi, Seiji [1 ]
Sasano, Tomoyuki [2 ]
Komura, Naoko [3 ]
机构
[1] Nara Med Univ, Dept Obstet & Gynecol, Nara 6348522, Japan
[2] Osaka Saiseikai Nakatsu Hosp, Dept Obstet & Gynecol, Osaka 5300012, Japan
[3] Kaizuka City Hosp, Dept Obstet & Gynecol, Osaka 5970015, Japan
关键词
MDSC; ovarian cancer; survival; therapeutic target; tumor microenvironment; TRANS-RETINOIC ACID; REVERSES IMMUNOSUPPRESSION; ANTITUMOR IMMUNITY; TUMOR-GROWTH; INHIBITION; DIFFERENTIATION; ACCUMULATION; PROGRESSION; EXPRESSION; CISPLATIN;
D O I
10.3390/cells10020329
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that exhibit immunosuppressive activity. They also directly stimulate tumor cell proliferation, metastasis, and angiogenesis. In ovarian cancer, there are increased numbers of circulating or tumor-infiltrating MDSCs, and increased frequencies of MDSCs are associated with a poor prognosis or an advanced clinical stage. Moreover, in murine models of ovarian cancer, MDSC depletion has shown significant growth-inhibitory effects and enhanced the therapeutic efficacy of existing anticancer therapies. In this review, we summarize the current knowledge on MDSC biology, clinical significance of MDSC, and potential MDSC-targeting strategies in ovarian cancer.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [1] Targeting Myeloid-Derived Suppressor Cells in Cancer
    Anani, Waseem
    Shurin, Michael R.
    TUMOR IMMUNE MICROENVIRONMENT IN CANCER PROGRESSION AND CANCER THERAPY, 2017, 1036 : 105 - 128
  • [2] Potential Novel Ovarian Cancer Treatment Targeting Myeloid-Derived Suppressor Cells
    Abiko, Kaoru
    Hayashi, Takuma
    Yamaguchi, Ken
    Mandai, Masaki
    Konishi, Ikuo
    CANCER INVESTIGATION, 2021, 39 (04) : 310 - 314
  • [3] Targeting myeloid-derived suppressor cells for cancer therapy
    Hongchao Tang
    Hao Li
    Zhijun Sun
    Cancer Biology & Medicine , 2021, (04) : 992 - 1009
  • [4] Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
    Wang, Yufei
    Jia, Anna
    Bi, Yujing
    Wang, Yuexin
    Yang, Qiuli
    Cao, Yejin
    Li, Yan
    Liu, Guangwei
    CANCERS, 2020, 12 (09) : 1 - 24
  • [5] Targeting myeloid-derived suppressor cells for cancer immunotherapy
    Yijun Liu
    Guowei Wei
    Wesley A. Cheng
    Zhenyuan Dong
    Han Sun
    Vincent Y. Lee
    Soung-Chul Cha
    D. Lynne Smith
    Larry W. Kwak
    Hong Qin
    Cancer Immunology, Immunotherapy, 2018, 67 : 1181 - 1195
  • [6] Targeting myeloid-derived suppressor cells for cancer therapy
    Hongchao Tang
    Hao Li
    Zhijun Sun
    Cancer Biology & Medicine, 2021, 18 (04) : 992 - 1009
  • [7] Targeting myeloid-derived suppressor cells for cancer therapy
    Tang, Hongchao
    Li, Hao
    Sun, Zhijun
    CANCER BIOLOGY & MEDICINE, 2021, 18 (04) : 992 - 1009
  • [8] Targeting myeloid-derived suppressor cells for cancer immunotherapy
    Liu, Yijun
    Wei, Guowei
    Cheng, Wesley A.
    Dong, Zhenyuan
    Sun, Han
    Lee, Vincent Y.
    Cha, Soung-Chul
    Smith, D. Lynne
    Kwak, Larry W.
    Qin, Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1181 - 1195
  • [9] Myeloid-derived suppressor cells in ovarian cancer: friend or foe?
    Walankiewicz, Monika
    Grywalska, Ewelina
    Polak, Grzegorz
    Kotarski, Jan
    Siwicka-Gieroba, Dorota J.
    Rolinski, Jacek
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2017, 42 (04) : 383 - 389
  • [10] Therapeutic targeting of myeloid-derived suppressor cells
    Ugel, Stefano
    Delpozzo, Federica
    Desantis, Giacomo
    Papalini, Francesca
    Simonato, Francesca
    Sonda, Nada
    Zilio, Serena
    Bronte, Vincenzo
    CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (04) : 470 - 481